Join five industry leaders as they unpack the transformative potential of artificial intelligence in the pharmaceutical industry, offering insights into real-world applications and the future of life sciences marketing in an era shaped by rapid technological evolution.
COMPASS Pathways’ CEO, Kabir Nath, has a clear vision for psychedelics—and is leading the way with the company’s focus on psilocybin and efforts to separate the science from the hype.
While large pharma investment in biotechs is down—as pharmas become more strategic in their selections—it is scarcely out, with the partnership dynamic between the two sides remaining strong.
In today's changing workplace environment—one forever altered by the pandemic and the new approaches it spawned—employees at all levels play a vital role in developing and advancing inclusive behaviors across an organization and beyond.
Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.
Attempts to capitalize on the region’s vibrant R&D scene are heating up.
The more serious shortages commonly involve sterile injectables.
Some new EU plans "fly in the face" of innovation, critics contend.
But will Washington’s dealmaking stance upend the momentum?
Conditions require a disciplined approach to drug pricing.
Pharma is built to overcome, but focus on fundamentals remains key.
Here in New Jersey, our home base, summer is officially upon us, and the Canadian wildfire smoke has just cleared from the air. I’m sure the bird watchers would attest to the eager chirping as both wildlife and humans greedily enjoy the beautiful weather. But even as the seasons change, so does the technology that drives innovation, as coverage in the July issue of Pharmaceutical Executive® attests.
Click the title above for a link to open the Pharmaceutical Executive June 2023 issue in an interactive PDF format.
